So Heun Lee
Overview
Explore the profile of So Heun Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
12
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Cheon J, Kim I, Kim K, Ryoo B, Jeong J, et al.
Cancer Med
. 2025 Jan;
14(1):e70560.
PMID: 39749730
Background: Numerous studies have explored the role of vitamin D in various cancers; however, its impact on advanced biliary tract cancers (BTC) within a prospective cohort remains to be investigated....
2.
Iavarone M, Alimenti E, Tada T, Shimose S, Suda G, Yoo C, et al.
Liver Cancer
. 2024 May;
13(2):215-226.
PMID: 38751557
Introduction: Lenvatinib is indicated for the forefront treatment of advanced hepatocellular carcinoma (aHCC), but its use may be limited by the risk of esophagogastric varices (EGV) bleeding. This study assessed...
3.
Lee S, Jeong H, Kim D, Jang S, Kim S, Yoon S, et al.
Cancer Res Treat
. 2024 Jan;
56(3):774-784.
PMID: 38291744
Purpose: Exon 20 insertion mutations (E20ins) in epidermal growth factor receptor (EGFR) or human epidermal growth factor receptor 2 (HER2) in non-small cell lung cancer (NSCLC) patients has become more...
4.
Kang S, Lee S, Lee H, Jeong H, Jeong J, Kim J, et al.
Eur J Cancer
. 2023 Jul;
191:112956.
PMID: 37473465
Background: The transition of human epidermal growth factor receptor 2 (HER2) status after neoadjuvant chemotherapy (NAC) in HER2-low breast cancer has not been thoroughly evaluated. Here, we evaluated the HER2...
5.
Lee S, Hwang D, Yoo C, Kim K, Kang S, Jeong J, et al.
Cancer Res Treat
. 2023 Mar;
55(3):956-968.
PMID: 36915253
Purpose: The benefit of adjuvant chemotherapy following curative-intent surgery in pancreatic ductal adenocarcinoma (PDAC) patients who had received neoadjuvant FOLFIRINOX is unclear. This study aimed to assess the survival benefit...
6.
Kang S, Yoo C, Lee S, Oh D, Song T, Lee S, et al.
Ther Adv Med Oncol
. 2022 May;
14:17588359221097190.
PMID: 35571606
Background: Adjuvant chemotherapy is the standard treatment after curative-intent surgery for pancreatic ductal adenocarcinoma (PDAC). The phase-3 ESPAC-4 trial demonstrated significantly improved overall survival (OS) with Gemcitabine plus capecitabine (GemCap)...